Skip to content

Predictive Value of Endometrial Cytokines in Endometrial Implantation in Cases of Intracytoplasmic Sperm Injection

Predictive Value of Endometrial Cytokines in Endometrial Implantation in Cases of Intracytoplasmic Sperm Injection

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02854514
Enrollment
80
Registered
2016-08-03
Start date
2015-04-30
Completion date
2017-01-31
Last updated
2016-11-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility

Keywords

endometrial -cytokines

Brief summary

For all women immediately after ovum retrieval from 80 women undergoing IVF, intra uterine salin flushing will be analyzed using a multiplex immunoassay for soluble regulators of implantation, namely Interleukin (IL)-1b, Tumor Necrosis Factor (TNF)-a,. In order to detect implantation predictors.

Detailed description

This is a prospective cohort study, performed on 80 women attending Obstetrics and Gynecology Department of Benha University Hospital for invitro fertilization/intracytoplasmic sperm injection treatment and private IVF centers. None undergoes more than one prior unsuccessful embryo transfer. Method of randomization: Simple random sample, which is a subset of individuals (a sample) chosen from a larger set (a population). Each individual is chosen randomly and entirely by chance, so each individual has the sample probability of being chosen at any stage during the sampling process, and each subset of k individuals has the same probability of being chosen for the sample as any other subset of k individuals (Yates et al., 2008). Methods: The patients will be subjected to the following: * History. * General examination. * Endometrial secretion aspiration. * Determination of the cytokine profile. * Detection of implantation rate. Inclusion criteria: 1. Age younger than 37 years. 2. Having a regular and proven ovulatory menstrual cycles with a length of 26-35 days. 3. Body mass index less than 35 kg/m2. 4. Serum follicle stimulating hormone and estradiol were within normal ranges. Indications of IVF: Tubal pathology, unexplained infertility, and male factor. Exclusion criteria: Gross uterine pathology. Steps of performance: All women having the inclusion criteria were subjected to super ovulation protocols followed by hcg adminstration when the follicles reached 18-20 mm . Ovum retrieval were done at 35 hours following hcg injection. Five millilitre of salin are injected intrauterine then aspirated after ovum retrieval.Endometrial secretions, aspirated immediately after ovum retrieval from 80 women undergoing IVF, will be analyzed using a multiplex immunoassay for soluble regulators of implantation, namely Interleukin (IL)-1b, Tumor Necrosis Factor (TNF)-a,. In order to detect implantation predictors.

Interventions

PROCEDUREAspiration of endometrial secretion

intra uterine flushing of the endometrial cavity by five millilitre of saline through embryo transfer catheter then aspirated then centrifuged then analyzed for detection of concentration of tumor necrosis factor a and interleukin 1 b

Sponsors

Benha University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
20 Years to 37 Years
Healthy volunteers
No

Inclusion criteria

1. Age younger than 37 years. 2. Having a regular and proven ovulatory menstrual cycles with a length of 26-35 days. 3. Body mass index less than 35 kg/m2. 4. Serum follicle stimulating hormone and estradiol were within normal ranges.

Exclusion criteria

* Gross uterine pathology.

Design outcomes

Primary

MeasureTime frame
Measurement of Tumor Necrosis Factor (TNF)-a2 days
Measurement of Interleukin (IL)-1b2 days

Secondary

MeasureTime frame
serum pregnancy test14 days

Countries

Egypt

Contacts

Primary Contactkhalid M Salama, MD
dr.khalid_sleem@yahoo.com01225861026
Backup ContactMohammed k Aloush, MD
mohamedkaloush@gmail.com01003541188

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 1, 2026